Audit and quality assessment of national persian registry of cardiovascular disease(N-PROVE) in terms of comorbidities, angiography, and angioplasty characteristics in Iran
Author(s):
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
BACKGROUND
The National Persian Registry of Cardiovascular Disease (N-PROVE) has been established to provide a comprehensive database of cardiovascular diseases in the Iranian community for further investigations and to develop national guidelines for the diagnosis, treatment, and prevention of cardiovascular disease (CVD). As with most clinical registries, a quality control audit is necessary to ensure a comprehensive and accurate registry; the current study aims to assess the validity and quality of the N-PROVE/Angiography/Percutaneous Coronary Intervention (PCI) registry.METHODS
The current cross-sectional quality assessment study serves as an example of data quality assessment in N-PROVE on a sample of patients registered in the N-PROVE/Angiography/PCI registry since 2020. Accordingly, data of 194 patients, including comorbidities, angiography, and angioplasty characteristics, were collected from the N-PROVE/Angiography/PCI registry as the main database and reevaluated by a panel consisting of a cardiologist and two coronary intervention fellowships as a test database.RESULTS
The quality control of the population-based healthcare database, the N-PROVE/PCI, revealed that the average error rate in terms of comorbidities, angiography characteristics, angioplasty characteristics, and in total were 3.8%, 2.3%, 3%, and 3.03%, respectively.CONCLUSION
According to the findings of this study, the N-PROVE/PCI registry had an average error of less than 4% in the assessed dimensions, including comorbidities, angiography, and angioplasty characteristics. Therefore, this registry appears valid and may be used for contemporary epidemiological studies.Keywords:
Language:
English
Published:
Arya Atherosclerosis, Volume:20 Issue: 1, Jan-Feb 2024
Pages:
20 to 30
https://www.magiran.com/p2734829
سامانه نویسندگان
مقالات دیگری از این نویسنده (گان)
-
The therapeutic potential of Ma'aljobon, a whey product, in primary hypertension: A double-blind randomized controlled trial
Asie Shojaii, Roshanak Ghods *, Fataneh Hashem-Dabaghian, Maryam Navabzadeh, Tooba Kazemi, Morné Weyers, Motlalepula G. Matsabisa
Avicenna Journal of Phytomedicine, Jan-Feb 2025 -
Cardiac rehabilitation is necessary for patients: Providing experiences from the launch of cardiac rehabilitation in a deprived province in Iran
Amirhossein Mirzaei Najmabadid, Maryam Sadat Rahimi, Seyed Mohammad Riahi,
Journal of Research in Medical Sciences, Sep 2024 -
The assessment of no-reflow phenomenon incidence in early versus delayed percutaneous coronary intervention following a primary fibrinolysis
Afshin Amirpour, Mohammad Amin Behjati *, Reihane Zavar, Ehsan Shirvani, Ehsan Zarepour, Razieh Hassannejad, Masoumeh Sadeghi, MD, Raheleh Janghorbanian Poodeh, , Shahin Sanaei, Nazanin Mahinparvar
Arya Atherosclerosis, Mar-Apr 2024 -
Does Adjunctive Prophylactic Intracoronary Infusion of Low Dose Alteplase Prevent No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention?
Mohammad Hashemi, Jalal Ostovan *, Masoumeh Sadeghi, Ehsan Shirvani, , Shahin Sanaei
Arya Atherosclerosis, Nov-Dec 2023